These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 37583902)
1. Cell-based medicinal products approved in the European Union: current evidence and perspectives. Bellino S; La Salvia A; Cometa MF; Botta R Front Pharmacol; 2023; 14():1200808. PubMed ID: 37583902 [TBL] [Abstract][Full Text] [Related]
2. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States. Iglesias-Lopez C; Obach M; Vallano A; Agustí A Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292 [TBL] [Abstract][Full Text] [Related]
3. The Current State of Advanced Therapy Medicinal Products in the Czech Republic. Kočí Z; Boráň T; Krůpa P; Kubinová Š Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533 [TBL] [Abstract][Full Text] [Related]
4. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe. Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211 [TBL] [Abstract][Full Text] [Related]
5. Call for More Effective Regulation of Clinical Trials with Advanced Therapy Medicinal Products Consisting of or Containing Genetically Modified Organisms in the European Union. Beattie S; Hum Gene Ther; 2021 Oct; 32(19-20):997-1003. PubMed ID: 33843251 [TBL] [Abstract][Full Text] [Related]
6. Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine. Goula A; Gkioka V; Michalopoulos E; Katsimpoulas M; Noutsias M; Sarri EF; Stavropoulos C; Kostakis A J Clin Med Res; 2020 Dec; 12(12):780-786. PubMed ID: 33447311 [TBL] [Abstract][Full Text] [Related]
7. Advanced therapy medicinal products: current and future perspectives. Hanna E; Rémuzat C; Auquier P; Toumi M J Mark Access Health Policy; 2016; 4():. PubMed ID: 27123193 [TBL] [Abstract][Full Text] [Related]
8. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective. Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215 [TBL] [Abstract][Full Text] [Related]
9. RESTORE Survey on the Public Perception of Advanced Therapies and ATMPs in Europe-Why the European Union Should Invest More! Goldsobel G; von Herrath C; Schlickeiser S; Brindle N; Stähler F; Reinke P; Aberman Z; Ofir R; Dessole G; Benvenuti S; Neves NM; Reis RL; Moll G; Volk HD Front Med (Lausanne); 2021; 8():739987. PubMed ID: 34765617 [TBL] [Abstract][Full Text] [Related]
10. Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products. Cuende N; Ciccocioppo R; Forte M; Galipeau J; Ikonomou L; Levine BL; Srivastava A; Zettler PJ Cytotherapy; 2022 Jul; 24(7):686-690. PubMed ID: 35545453 [TBL] [Abstract][Full Text] [Related]
11. Surgery Versus ATMPs: An Example From Ophthalmology. Magrelli FM; Merra A; Pellegrini G Front Bioeng Biotechnol; 2020; 8():440. PubMed ID: 32587848 [TBL] [Abstract][Full Text] [Related]
12. European regulatory tools for advanced therapy medicinal products. Flory E; Reinhardt J Transfus Med Hemother; 2013 Dec; 40(6):409-12. PubMed ID: 24474890 [TBL] [Abstract][Full Text] [Related]
13. A pipeline analysis of advanced therapy medicinal products. Wilkins GC; Lanyi K; Inskip A; Ogunbayo OJ; Brhlikova P; Craig D Drug Discov Today; 2023 May; 28(5):103549. PubMed ID: 36963609 [TBL] [Abstract][Full Text] [Related]
14. Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving? Boráň T; Menezes-Ferreira M; Reischl I; Celis P; Ferry N; Gänsbacher B; Krafft H; Lipucci di Paola M; Sladowski D; Salmikangas P Hum Gene Ther Clin Dev; 2017 Sep; 28(3):126-135. PubMed ID: 28510497 [TBL] [Abstract][Full Text] [Related]
15. Regulation of advanced therapy medicinal products in Europe and the role of academia. Pearce KF; Hildebrandt M; Greinix H; Scheding S; Koehl U; Worel N; Apperley J; Edinger M; Hauser A; Mischak-Weissinger E; Dickinson AM; Lowdell MW Cytotherapy; 2014 Mar; 16(3):289-97. PubMed ID: 24113428 [TBL] [Abstract][Full Text] [Related]
16. Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries. Coppens DGM; Hoekman J; De Bruin ML; Slaper-Cortenbach ICM; Leufkens HGM; Meij P; Gardarsdottir H Cytotherapy; 2020 Oct; 22(10):592-600. PubMed ID: 32563611 [TBL] [Abstract][Full Text] [Related]
17. Advanced Therapy medicinal products for autologous chondrocytes and comparison of regulatory systems in target countries. Kim J; Park J; Song SY; Kim E Regen Ther; 2022 Jun; 20():126-137. PubMed ID: 35582708 [TBL] [Abstract][Full Text] [Related]
18. EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation. Detela G; Lodge A Mol Ther Methods Clin Dev; 2019 Jun; 13():205-232. PubMed ID: 30815512 [TBL] [Abstract][Full Text] [Related]
19. Prospects of Advanced Therapy Medicinal Products-Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives. Bakopoulou A J Endod; 2020 Sep; 46(9S):S175-S188. PubMed ID: 32950189 [TBL] [Abstract][Full Text] [Related]